NZ707081A - Agent for preventing or improving decline in brain function - Google Patents

Agent for preventing or improving decline in brain function

Info

Publication number
NZ707081A
NZ707081A NZ707081A NZ70708113A NZ707081A NZ 707081 A NZ707081 A NZ 707081A NZ 707081 A NZ707081 A NZ 707081A NZ 70708113 A NZ70708113 A NZ 70708113A NZ 707081 A NZ707081 A NZ 707081A
Authority
NZ
New Zealand
Prior art keywords
decreased
agent
brain function
salt
preventing
Prior art date
Application number
NZ707081A
Other languages
English (en)
Inventor
Kota Kumagai
Masahiko Morita
Takahiro Hara
Kohji Fukunaga
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Publication of NZ707081A publication Critical patent/NZ707081A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ707081A 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function NZ707081A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012238542 2012-10-30
PCT/JP2013/080053 WO2014069667A1 (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Publications (1)

Publication Number Publication Date
NZ707081A true NZ707081A (en) 2019-03-29

Family

ID=50627559

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ707081A NZ707081A (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Country Status (9)

Country Link
US (2) US10905705B2 (enExample)
EP (1) EP2914270B1 (enExample)
JP (1) JP6166786B2 (enExample)
AU (1) AU2013339058B2 (enExample)
CA (1) CA2889109C (enExample)
ES (1) ES2906614T3 (enExample)
NZ (1) NZ707081A (enExample)
PL (1) PL2914270T3 (enExample)
WO (1) WO2014069667A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2914270B1 (en) 2012-10-30 2022-01-12 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
US11583546B2 (en) 2014-04-30 2023-02-21 Kyowa Hakko Bio Co., Ltd. Administration of citicoline to improve cognitive performance, attentional performance, and motor function
CN117069780A (zh) 2016-10-06 2023-11-17 协和发酵生化株式会社 胞苷二磷酸胆碱的晶体及其制造方法
JP7142284B2 (ja) * 2017-06-06 2022-09-27 株式会社らいむ 神経伸長促進剤
JP2019218284A (ja) * 2018-06-18 2019-12-26 オンガネジャパン株式会社 若齢者学習能力向上のための経口組成物及び若齢者の学習能力を向上させる方法
WO2025258678A1 (ja) * 2024-06-13 2025-12-18 キリンホールディングス株式会社 神経回路の興奮を促進するための組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213000A1 (en) * 1995-03-06 1996-09-12 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP5931325B2 (ja) * 2008-01-30 2016-06-08 協和発酵バイオ株式会社 注意集中力向上剤
CN102316852A (zh) * 2009-02-11 2012-01-11 丽卡实验有限公司 脂质胞二磷胆碱注射液
ES2345802B1 (es) * 2009-03-30 2011-09-08 Hospital Clinic I Provincial De Barcelona Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus.
EP2914270B1 (en) 2012-10-30 2022-01-12 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function

Also Published As

Publication number Publication date
CA2889109C (en) 2020-09-01
AU2013339058B2 (en) 2017-09-07
EP2914270A4 (en) 2016-03-16
WO2014069667A1 (en) 2014-05-08
US20150306125A1 (en) 2015-10-29
AU2013339058A1 (en) 2015-05-07
US20210113601A1 (en) 2021-04-22
US11738037B2 (en) 2023-08-29
EP2914270A1 (en) 2015-09-09
US10905705B2 (en) 2021-02-02
EP2914270B1 (en) 2022-01-12
JP2015535241A (ja) 2015-12-10
PL2914270T3 (pl) 2022-03-14
ES2906614T3 (es) 2022-04-19
CA2889109A1 (en) 2014-05-08
JP6166786B2 (ja) 2017-07-19

Similar Documents

Publication Publication Date Title
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MX379044B (es) Direccion de elementos reguladores distales de bcl11a para reinduccion de hemoglobina fetal.
MX353874B (es) Gotas para los ojos que contienen diquafosol.
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
WO2013022846A3 (en) Flavonoid compounds
WO2013178965A3 (fr) Principes actifs activateurs de la mitophagie des cellules cutanées et utilisation pour améliorer l'état de la peau
PL2854910T3 (pl) Poziomy ceramidu w leczeniu i zapobieganiu infekcjom
IN2014KN02914A (enExample)
JP2015535241A5 (enExample)
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
GB2521979A (en) A method, use, and dietary supplement composition for at least treating an atopic or non-atopic disorder in a patient
PT3300482T (pt) Uso de prg4 para melhorar a acuidade visual dinâmica e as aberrações de ordem superior
MX353580B (es) Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel.
EP2905337A4 (en) AMPHIREGULIN SPECIFIC DOUBLE HELIX OLIGO RNA, DOUBLE HELIX OLIGO RNA STRUCTURE WITH THE DOUBLE HELIX OLIGO RNA AND COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASES THEREWITH
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
IN2014MN01551A (enExample)
EA201500778A1 (ru) Композиция по уходу за кожей
WO2014031982A3 (en) Methods and compositions for treating pain
NZ706862A (en) Agent for preventing or improving decline in brain function
WO2010026213A3 (en) Treatment of scleroderma
WO2015074667A3 (en) Composition for dermatitis
WO2013107687A3 (fr) Compositions dermo-cosmétiques à base d'une association synergique d'argent colloïdal et d'acide désoxyribonucléique
HK1203379A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
WO2013038200A3 (en) Neurodevelopmental disorders

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2020 BY CPA GLOBAL

Effective date: 20190912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2021 BY CPA GLOBAL

Effective date: 20200917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2022 BY CPA GLOBAL

Effective date: 20210916

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2023 BY CPA GLOBAL

Effective date: 20220915

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2024 BY CPA GLOBAL

Effective date: 20230914

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250918